To support the free and open dissemination of research findings and information on alcoholism and alcohol-related problems. To encourage open access to peer-reviewed articles free for all to view.

For full versions of posted research articles readers are encouraged to email requests for "electronic reprints" (text file, PDF files, FAX copies) to the corresponding or lead author, who is highlighted in the posting.


Wednesday, February 1, 2012

The effects of TPA023, a GABAAα2,3 subtype-selective partial agonist, on essential tremor in comparison to alcohol

Essential tremor (ET) is a relatively frequent neurological disorder that responds in some patients to gamma-aminobutyric acid A (GABAA) agonists such as the benzodiazepines. Partial subtype-selective GABAA agonists may have an improved side effect profile compared to non-selective GABAA agonists. However, it is unknown which GABAA subtypes are involved in the therapeutic effects of benzodiazepines in ET.

The effects of 2 mg TPA023, a GABA
A α2,3 subtype-selective partial agonist, on ET were compared to the effects of a stable alcohol level (0.6 g/L) and placebo in nine patients with ET. Tremor evaluation included laboratory accelerometry and a performance-based scale. Additional measurements were performed to evaluate other effects on the central nervous system (CNS).

Alcohol significantly diminished tremor symptoms in the postural and kinetic condition, as assessed by laboratory accelerometry, but the performance-based rating scale was unaffected.

Tremor was also reduced after TPA023 treatment in the kinetic condition, albeit not significantly. Additionally, TPA023 decreased saccadic peak velocity, while alcohol decreased subjective feelings of alertness.

This study showed that alcohol reduced maximum tremor power, as assessed by laboratory accelerometry, unlike TPA023, which decreased tremor symptoms to some extent but not significantly.

This study showed that treatment with an α2,3 subunit-selective GABA
A partial agonist was less effective than a stable level of alcohol in reducing ET symptoms.

These results provide no support for a therapeutic role of TPA023 in the suppression of ET symptoms.

Read Full Abstract

Request Reprint E-Mail: